ProCE Banner Activity

ELEVATE-TN 6-Yr Update: Acalabrutinib ± Obinutuzumab vs Obinutuzumab + Chlorambucil in Treatment-Naive CLL

Conference Coverage

After a median follow-up of approximately 6 years, acalabrutinib with or without obinutuzumab maintained a significantly improved PFS vs chlorambucil plus obinutuzumab in patients with treatment-naive CLL with no new safety concerns.

Released: December 13, 2023


Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from AbbVie Inc., AstraZeneca, Daiichi Sankyo, Inc., Merck Sharp & Dohme LLC, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Inc, and Seagen Inc.

AbbVie Inc.


Daiichi Sankyo, Inc.

Merck Sharp & Dohme, LLC

Novartis Pharmaceuticals Corporation

Regeneron Pharmaceuticals, Inc

Seagen Inc.